Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand‐1 (PD‐L1) expression and increases anti‐tumour effects of T cells in multiple myeloma
Author:
Affiliation:
1. Institute for Myeloma and Bone Cancer Research West Hollywood CA USA
2. Oncotherapeutics West Hollywood CA USA
Publisher
Wiley
Subject
Hematology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17282
Reference43 articles.
1. Immunodeficiency and immunotherapy in multiple myeloma
2. The diverse functions of the PD1 inhibitory pathway
3. Regulation and Function of the PD-L1 Checkpoint
4. Immunosuppressive Effects of Multiple Myeloma Are Overcome by PD-L1 Blockade
5. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Emerging Targets and Therapeutics in Immuno-Oncology: Insights from Landscape Analysis;Journal of Medicinal Chemistry;2024-05-24
2. A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone;Targeted Oncology;2024-04-20
3. Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma;Oncotarget;2024-02-05
4. Identification of an angiogenesis-related risk score model for survival prediction and immunosubtype screening in multiple myeloma;Aging;2024-02-05
5. Immune checkpoint inhibitors for multiple myeloma immunotherapy;Experimental Hematology & Oncology;2023-11-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3